Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Standard BioTools  (Stock symbol: LAB )

7000 Shoreline Court
South San Francisco, CA 94080
Website Company Summary Management Team

CEO: Chris Linthwaite (10/31/2016)
President/COO/Operations: Alex Kim (01/24/2022)
General Management: Grace Yow (2006) ; Steve McPhail
Finance: Vikram Jog (02/29/2008)
Technology: Robert C Jones (08/24/2005)
Sales/Marketing: Dominique Remy-Renou
Business Development: Colin McCracken
General Counsel/Legal: Nick Khadder

Outside board: (May no longer be on the board) Gerhard F Burbach (Thoratec President/CEO) Michael W Hunkapiller (Applied Biosystems Group) Raymond J Whitaker (EuclidSR Partners General Partner) Noah Knauf (Bond Partner) Jeff Bird (Forty Seven Lead Director);  Martin Madaus (Millipore Former CEO) Patrick S Jones (Gemplus International S.A. Former CFO) Samuel D Colella (Versant Ventures) Kenneth Nussbacher (Affymetrix Fellow) John A Young (HP CEO)
Former outside board: Bruce Burrows (Hydrotech CEO) Matthew Collier (Avocet CEO);  Pawel Fludzinski (Lilly Bioventures) Hingge Hsu (Lehman Brothers) Elaine V Jones (Euclid Partners)
Former advisory board: Camille D Samuels (Versant Ventures Managing Director)

Business description: Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at, or connect with us on Twitter, Facebook, LinkedIn, and YouTube.
Customers include: GlaxoSmithKline ;  KUMAMOTO UNIVERSITY ;  LEIDEN UNIVERSITY MEDICAL CENTER ;  University of Texas Southwestern Medical Center
Partners include: GlaxoSmithKlineIn-Q-Tel ;  Advent Health ;  Mayo Clinic ;  Renown Health

Rounds: 7
Recent Fundings: Nov 2009   Sep 2009
Capital raised: 125.2M
Last Round: 7.5M
Ownership: Public   Ipo Filing
Stock Symbol: LAB
VCs include: Alloy VenturesInterWest PartnersVersant VenturesSightLine PartnersEDB Investments;  Invus;  Tenex Medical Investors;  US Bancorp Piper Jaffray;  Lehman Brothers Healthcare Fund;  Jaffray Ventures;  Wasatch Advisors ;  AllianceBernstein ;  EuclidSR Partners;  Cross Creek Capital;  Casdin Capital
Angels/other VCs: Michael Egholm (Danaher Life Sciences)

Last Tweets


Last Mentions

Record updated: Apr 2022
Sector: Biotech
Year Founded: 1999
Headcount: 601-700 as of Apr 2022
Rounds: 7
Recent Fundings: Nov 2009   Sep 2009
Capital Raised: 125.2M
Last Round: 7.5M
Ownership: Public   Ipo Filing
Stock Symbol: LAB